DDIT3 and diffuse large B-cell lymphoma: FOXP1 has been identified as an ABC-DLBCL marker [15], whose expression correlated with poor clinical outcome in both CHOP [21, 22] and R-CHOP [23, 24] treated DLBCL patients.